Prioritising access to cancer drugs
- PMID: 34973227
- DOI: 10.1016/S1470-2045(21)00637-9
Prioritising access to cancer drugs
Conflict of interest statement
DLS has received honoraria from AstraZeneca, MSD Oncology, Zuellig Pharma, and Kalbe Farma; is a member of the speakers bureau of MSD, Abbott Nutrition, and Lilly; has a consulting role at Unilab, Pfizer, and Roche; and has received support for attending meetings and travel for conventions from Unilab and Pfizer. All other authors declare no competing interests.
Comment in
-
Prioritising access to cancer drugs.Lancet Oncol. 2022 Jan;23(1):e1. doi: 10.1016/S1470-2045(21)00641-0. Lancet Oncol. 2022. PMID: 34973219 No abstract available.
Comment on
-
Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey.Lancet Oncol. 2021 Oct;22(10):1367-1377. doi: 10.1016/S1470-2045(21)00463-0. Epub 2021 Sep 21. Lancet Oncol. 2021. PMID: 34560006 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
